VISTAGEN THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
VISTAGEN THERAPEUTICS INC. - More news...
VISTAGEN THERAPEUTICS INC. - More news...
- Vistagen Appoints Cindy Anderson as Chief Financial Officer
- Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
- Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
- Thinking about buying stock in FlexShopper, HH&L Acquisition, Vistagen Therapeutics, Vivos Therapeutics, or Missfresh?
- Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
- Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
- Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
- Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
- Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
- Vistagen Regains Full Compliance with Nasdaq Listing Requirements
- Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
- Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
- Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
- Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
- Vistagen to Present at Jefferies 2023 Global Healthcare Conference
- Vistagen Announces Stockholder-Approved Reverse Stock Split
- Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
- Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
- Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
- Vistagen Receives New European Patent for AV-101
- FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
- Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
- Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
- Vistagen to Present at Cowen 43rd Annual Health Care Conference
- Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
- Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
- Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
- Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
- Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder